Glutamatın Santral Sinir Sistemindeki Patolojik Etkileri

Ottersen OP, Storm-Mathisen J. Glutamate- and GABA-containing neurons in the mouse and rat brain, as demonstrated with a new immunocytochemical technique. J Comp Neurol. 1984;229(3):374-392.

Braitenberg V SA. Cortex: statistics and geometry of neuronal connectivity Berlin: Springer Science Business Media 2013.

Hassel B, Dingledine R. Glutamate and Glutamate Receptors. Basic Neurochemistry. 2012:342-366.

Peng L, Hertz L, Huang R, et al. Utilization of glutamine and of TCA cycle constituents as precursors for transmitter glutamate and GABA. Dev Neurosci. 1993;15(3-5):367-377.

McKenna MC. The glutamate-glutamine cycle is not stoichiometric: fates of glutamate in brain. J Neurosci Res. 2007;85(15):3347-3358.

Omote H, Miyaji T, Juge N, et al. Vesicular neurotransmitter transporter: bioenergetics and regulation of glutamate transport. Biochemistry. 2011;50(25):5558-5565.

Dobrek L, Thor P. Glutamate NMDA receptors in pathophysiology and pharmacotherapy of selected nervous system diseases. Postepy higieny i medycyny doswiadczalnej (Online). 2011;65:338-346.

Danbolt NC. Glutamate uptake. Progress in neurobiology. 2001;65(1):1-105.

Shen J, Petersen KF, Behar KL, et al. Determination of the rate of the glutamate/glutamine cycle in the human brain by in vivo 13C NMR. Proceedings of the National Academy of Sciences of the United States of America. 1999;96(14):8235-8240.

Nakanishi S. Metabotropic glutamate receptors: synaptic transmission, modulation, and plasticity. Neuron. 1994;13(5):1031-1037.

Iacovelli L, Bruno V, Salvatore L, et al. Native group-III metabotropic glutamate receptors are coupled to the mitogen-activated protein kinase/phosphatidylinositol-3-kinase pathways. Journal of neurochemistry. 2002;82(2):216-223.

Nicoletti F, Bockaert J, Collingridge GL, et al. Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology. 2011;60(7-8):1017-1041.

Traynelis SF, Wollmuth LP, McBain CJ, et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev. 2010;62(3):405-496.

Craig AM, Blackstone CD, Huganir RL, et al. The distribution of glutamate receptors in cultured rat hippocampal neurons: postsynaptic clustering of AMPA-selective subunits. Neuron. 1993;10(6):1055-1068.

Porter RH, Eastwood SL, Harrison PJ. Distribution of kainate receptor subunit mRNAs in human hippocampus, neocortex and cerebellum, and bilateral reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia. Brain Res. 1997;751(2):217-231.

Greger IH, Khatri L, Kong X, et al. AMPA receptor tetramerization is mediated by Q/R editing. Neuron. 2003;40(4):763-774.

Sanz-Clemente A, Nicoll RA, Roche KW. Diversity in NMDA receptor composition: many regulators, many consequences. Neuroscientist. 2013;19(1):62-75.

Glasgow NG, Siegler Retchless B, Johnson JW. Molecular bases of NMDA receptor subtype-dependent properties. J Physiol. 2015;593(1):83-95.

Sears SM, Hewett SJ. Influence of glutamate and GABA transport on brain excitatory/inhibitory balance. Exp Biol Med (Maywood). 2021;246(9):1069-1083.

Erreger K, Dravid SM, Banke TG, et al. Subunit-specific gating controls rat NR1/NR2A and NR1/NR2B NMDA channel kinetics and synaptic signalling profiles. J Physiol. 2005;563(Pt 2):345-358.

Zhou X, Ding Q, Chen Z, et al. Involvement of the GluN2A and GluN2B subunits in synaptic and extrasynaptic N-methyl-D-aspartate receptor function and neuronal excitotoxicity. The Journal of biological chemistry. 2013;288(33):24151-24159.

Hardingham GE, Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nature reviews Neuroscience. 2010;11(10):682-696.

Hardingham GE, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nature neuroscience. 2002;5(5):405-414.

Bergles DE, Tzingounis AV, Jahr CE. Comparison of coupled and uncoupled currents during glutamate uptake by GLT-1 transporters. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2002;22(23):10153-10162.

Aizawa H, Sun W, Sugiyama K, et al. Glial glutamate transporter GLT-1 determines susceptibility to spreading depression in the mouse cerebral cortex. Glia. 2020;68(12):2631-2642.

Chung EK, Chen LW, Chan YS, et al. Downregulation of glial glutamate transporters after dopamine denervation in the striatum of 6-hydroxydopamine-lesioned rats. J Comp Neurol. 2008;511(4):421-437.

Holmer HK, Keyghobadi M, Moore C, et al. l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience. 2005;136(1):333-341.

Lau CG, Zukin RS. NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nature reviews Neuroscience. 2007;8(6):413-426.

Olney JW, Ho OL. Brain damage in infant mice following oral intake of glutamate, aspartate or cysteine. Nature. 1970;227(5258):609-611.

Prentice H, Modi JP, Wu JY. Mechanisms of Neuronal Protection against Excitotoxicity, Endoplasmic Reticulum Stress, and Mitochondrial Dysfunction in Stroke and Neurodegenerative Diseases. Oxidative medicine and cellular longevity. 2015;2015:964518.

Connolly NM, Prehn JH. The metabolic response to excitotoxicity - lessons from single-cell imaging. Journal of bioenergetics and biomembranes. 2015;47(1-2):75-88.

Zivin JA, Choi DW. Stroke therapy. Sci Am. 1991;265(1):56-63.

Albin RL, Greenamyre JT. Alternative excitotoxic hypotheses. Neurology. 1992;42(4):733-738.

Castilho RF, Hansson O, Ward MW, et al. Mitochondrial control of acute glutamate excitotoxicity in cultured cerebellar granule cells. The Journal of neuroscience : the official journal of the Society for Neuroscience. 1998;18(24):10277-10286.

Ward MW, Huber HJ, Weisová P, et al. Mitochondrial and plasma membrane potential of cultured cerebellar neurons during glutamate-induced necrosis, apoptosis, and tolerance. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2007;27(31):8238-8249.

D'Orsi B, Bonner H, Tuffy LP, et al. Calpains Are Downstream Effectors of bax-Dependent Excitotoxic Apoptosis. 2012;32(5):1847-1858.

Kemp JA, McKernan RM. NMDA receptor pathways as drug targets. Nature neuroscience. 2002;5 Suppl:1039-1042.

Lipton S. Pathologically-Activated Therapeutics for Neuroprotection: Mechanism of NMDA Receptor Block by Memantine and S-Nitrosylation. Current drug targets. 2007;8:621-632.

Lewerenz J, Maher P, Methner A. Regulation of xCT expression and system $$ x_{text{c}}^{ - } $$function in neuronal cells. Amino Acids. 2012;42(1):171-179.

Murphy TH, Miyamoto M, Sastre A, et al. Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress. Neuron. 1989;2(6):1547-1558.

Maher P, van Leyen K, Dey PN, et al. The role of Ca(2+) in cell death caused by oxidative glutamate toxicity and ferroptosis. Cell calcium. 2018;70:47-55.

Tan S, Sagara Y, Liu Y, et al. The regulation of reactive oxygen species production during programmed cell death. The Journal of cell biology. 1998;141(6):1423-1432.

Pallast S, Arai K, Wang X, et al. 12/15-Lipoxygenase targets neuronal mitochondria under oxidative stress. Journal of neurochemistry. 2009;111(3):882-889.

Seiler A, Schneider M, Förster H, et al. Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase dependent- and AIF-mediated cell death. Cell metabolism. 2008;8(3):237-248.

Armada-Moreira A, Gomes JI, Pina CC, et al. Going the Extra (Synaptic) Mile: Excitotoxicity as the Road Toward Neurodegenerative Diseases. Frontiers in cellular neuroscience. 2020;14:90.

Baker DA, Xi ZX, Shen H, et al. The origin and neuronal function of in vivo nonsynaptic glutamate. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2002;22(20):9134-9141.

Nelson PT, Braak H, Markesbery WR. Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. Journal of neuropathology and experimental neurology. 2009;68(1):1-14.

Brito-Moreira J, Paula-Lima AC, Bomfim TR, et al. Aβ oligomers induce glutamate release from hippocampal neurons. Current Alzheimer research. 2011;8(5):552-562.

Li S, Jin M, Koeglsperger T, et al. Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2011;31(18):6627-6638.

Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416(6880):535-539.

Ferreira IL, Bajouco LM, Mota SI, et al. Amyloid beta peptide 1-42 disturbs intracellular calcium homeostasis through activation of GluN2B-containing N-methyl-d-aspartate receptors in cortical cultures. Cell calcium. 2012;51(2):95-106.

Schafe GE, Atkins CM, Swank MW, et al. Activation of ERK/MAP kinase in the amygdala is required for memory consolidation of pavlovian fear conditioning. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2000;20(21):8177-8187.

Mulholland PJ, Luong NT, Woodward JJ, et al. Brain-derived neurotrophic factor activation of extracellular signal-regulated kinase is autonomous from the dominant extrasynaptic NMDA receptor extracellular signal-regulated kinase shutoff pathway. Neuroscience. 2008;151(2):419-427.

Brawek B, Garaschuk O. Network-wide dysregulation of calcium homeostasis in Alzheimer's disease. Cell and tissue research. 2014;357(2):427-438.

Angelova PR, Abramov AY. Interaction of neurons and astrocytes underlies the mechanism of Aβ-induced neurotoxicity. Biochemical Society transactions. 2014;42(5):1286-1290.

Merlini M, Meyer EP, Ulmann-Schuler A, et al. Vascular β-amyloid and early astrocyte alterations impair cerebrovascular function and cerebral metabolism in transgenic arcAβ mice. Acta neuropathologica. 2011;122(3):293-311.

Descalzi G, Gao V, Steinman MQ, et al. Lactate from astrocytes fuels learning-induced mRNA translation in excitatory and inhibitory neurons. Communications Biology. 2019;2(1):247.

Yamamoto M, Kiyota T, Walsh SM, et al. Cytokine-mediated inhibition of fibrillar amyloid-beta peptide degradation by human mononuclear phagocytes. Journal of immunology (Baltimore, Md : 1950). 2008;181(6):3877-3886.

Hu S, Sheng WS, Ehrlich LC, et al. Cytokine effects on glutamate uptake by human astrocytes. Neuroimmunomodulation. 2000;7(3):153-159.

Ralay Ranaivo H, Craft JM, Hu W, et al. Glia as a therapeutic target: selective suppression of human amyloid-beta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2006;26(2):662-670.

Barger SW, Basile AS. Activation of microglia by secreted amyloid precursor protein evokes release of glutamate by cystine exchange and attenuates synaptic function. Journal of neurochemistry. 2001;76(3):846-854.

Wang J, Wang F, Mai D, et al. Molecular Mechanisms of Glutamate Toxicity in Parkinson's Disease. Frontiers in neuroscience. 2020;14:585584.

Jankovic J. Parkinson's disease: clinical features and diagnosis. Journal of neurology, neurosurgery, and psychiatry. 2008;79(4):368-376.

Lotharius J, Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nature reviews Neuroscience. 2002;3(12):932-942.

Wang X, Wang J, Lin S, et al. Sp1 is involved in H 2 O 2-induced PUMA gene expression and apoptosis in colorectal cancer cells. 2008;27(1):1-10.

Saggu H, Cooksey J, Dexter D, et al. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. 1989;53(3):692-697.

Yang Y, Gozen O, Vidensky S, et al. Epigenetic regulation of neuron‐dependent induction of astroglial synaptic protein GLT1. 2010;58(3):277-286.

Gu X-L, Long C-X, Sun L, et al. Astrocytic expression of Parkinson's disease-related A53T α-synuclein causes neurodegeneration in mice. 2010;3(1):1-16.

Zhang W, Wang T, Pei Z, et al. Aggregated α‐synuclein activates microglia: a process leading to disease progression in Parkinson's disease. 2005;19(6):533-542.